Searched for
KIRAN M SHAW
Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...- Intellectual curiosity & infectious optimism: Industry cheers Kunal Shah's new role as WhatsApp HeadIndia Inc. is celebrating Kunal Shah's appointment as WhatsApp head, hailing it as a milestone for Indian startup leadership. Industry lead...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- GSK in talks to buy cancer biotech Nuvalent for more than $9 billionBritish drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...
- Biocon chief Kiran Mazumdar-Shaw questions source of reports claiming that she had offered to repair roads in BengaluruKiran Mazumdar-Shaw, the entrepreneurial force behind Biocon, has playfully dismissed claims that she proposed funding for Bengaluru's road...
- Citigroup has buy on Biocon, target price Rs 350Citi gave the buy rating after the company and Mylan announced launch of Ogivri in the US.
- Buy Biocon, target Rs 660: Manas JaiswalBuy Biocon Ltd. at a price target of Rs 660.0 and a stop loss at Rs 630 from the entry point.
- Buy Biocon, target Rs 625: Manas JaiswalBuy Biocon Ltd. at a price target of Rs 625.0 and a stop loss at Rs 594 from entry point.
- Buy Biocon, target Rs 668: Kunal BothraBuy Biocon Ltd. at a price target of Rs 668.0 and a stop loss at Rs 622 from entry point.
- Buy Biocon, target Rs 642: Jay ThakkarBuy Biocon Ltd. at a price target of Rs 642.0 and a stop loss at Rs 606 from entry point.
- Buy Biocon, target Rs 641: Dr CK NarayanBuy Biocon Ltd. at a price target of Rs 641.0 and a stop loss at Rs 620 from entry point.
- An unequal music: Biocon MD Kiran Mazumdar-Shaw recalls being a girl child and biases facedShaw recently recollected a personal memory to highlight her own run-in with the bias.
- Kiran M Shaw appointed 'Knight of Legion of Honour' by FranceThe award will be conferred on behalf of the President of the French Republic at a special ceremony later this year, Biocon said here in a ...
- Aircraft shifted to HAL due to metro project work in 2009 returns to Minsk Square as a sculptureA made-to-scale stainless steel model of an aircraft, sculpted by artist Yusuf Arakkal, could soon adorn Minsk Square in the heart of Benga...
- Kiran Mazumdar Shaw elected first non-executive chairman of ABLEP M Murali, Managing Director and CEO, Evolva Biotech, was re-elected as President for a second term at the meet here last week, an ABLE re...
- Planning to list Syngene, selling stake part of IPO process: Kiran Mazumdar Shaw, Biocon'Syngene is India’s leading research services company in discovery and development space, especially in the pharmaceutical sector,' says Ma...
- Infosys is resilient enough: Kiran Mazumdar-ShawBiocon chairman Kiran Mazumdar-Shaw was named to the board of directors of Infosys last week, the day the company saw one of its most high-...
- Biocon's Shaw looks at acquisitions in IPsIndian pharma firms are increasing their market presence globally. Read Biocon's next strategic plans.
Load More
